I

n a setback for the pharmaceutical industry, the Nevada state assembly on Thursday voted in favor of a controversial bill aimed at lowering prices for diabetes medicines. The legislation, which passed the state senate last week, now goes to Governor Brian Sandoval.

The bill is designed to lower costs by requiring drug makers to report pricing histories, disclose costs, and notify state officials and insurers in advance of price hikes above inflation. And a recently added amendment would also require drug companies to disclose rebates paid to pharmacy benefit managers, the middlemen that negotiate favorable insurance coverage.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hi Ed I am out of pocket until after Memorial Day. I would Contact Genia Long at Analysis Group about CRADAs . She is more up to date than me Henry

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine